207 related articles for article (PubMed ID: 31468511)
1. Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease.
Albassam F; Longoni G; Yea C; Wilbur C; Grover SA; Yeh EA
Dev Med Child Neurol; 2020 Mar; 62(3):390-395. PubMed ID: 31468511
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders.
Konuskan B; Yildirim M; Gocmen R; Okur TD; Polat I; Kilic H; Saltik S; Ozturk Z; Gucuyener K; Altunbasak S; Celik T; Kose G; Yilmaz A; Komur M; Kayilioglu H; Anlar B
Mult Scler Relat Disord; 2018 Nov; 26():1-7. PubMed ID: 30212767
[TBL] [Abstract][Full Text] [Related]
3. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Hacohen Y; Wong YY; Lechner C; Jurynczyk M; Wright S; Konuskan B; Kalser J; Poulat AL; Maurey H; Ganelin-Cohen E; Wassmer E; Hemingway C; Forsyth R; Hennes EM; Leite MI; Ciccarelli O; Anlar B; Hintzen R; Marignier R; Palace J; Baumann M; Rostásy K; Neuteboom R; Deiva K; Lim M
JAMA Neurol; 2018 Apr; 75(4):478-487. PubMed ID: 29305608
[TBL] [Abstract][Full Text] [Related]
4. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases.
Baumann M; Hennes EM; Schanda K; Karenfort M; Kornek B; Seidl R; Diepold K; Lauffer H; Marquardt I; Strautmanis J; Syrbe S; Vieker S; Höftberger R; Reindl M; Rostásy K
Mult Scler; 2016 Dec; 22(14):1821-1829. PubMed ID: 26869530
[TBL] [Abstract][Full Text] [Related]
5. Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination.
Zhou J; Lu X; Zhang Y; Ji T; Jin Y; Xu M; Bao X; Zhang Y; Xiong H; Chang X; Jiang Y; Wu Y
Mult Scler Relat Disord; 2019 Feb; 28():4-10. PubMed ID: 30529926
[TBL] [Abstract][Full Text] [Related]
6. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
7. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies.
Lee HJ; Kim B; Waters P; Woodhall M; Irani S; Ahn S; Kim SJ; Kim SM
J Neuroinflammation; 2018 Oct; 15(1):302. PubMed ID: 30382857
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases.
Durozard P; Rico A; Boutiere C; Maarouf A; Lacroix R; Cointe S; Fritz S; Brunet C; Pelletier J; Marignier R; Audoin B
Ann Neurol; 2020 Feb; 87(2):256-266. PubMed ID: 31725931
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
Nepal G; Kharel S; Coghlan MA; Rayamajhi P; Ojha R
J Neuroimmunol; 2022 Mar; 364():577812. PubMed ID: 35063726
[TBL] [Abstract][Full Text] [Related]
10. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
Ramanathan S; Mohammad S; Tantsis E; Nguyen TK; Merheb V; Fung VSC; White OB; Broadley S; Lechner-Scott J; Vucic S; Henderson APD; Barnett MH; Reddel SW; Brilot F; Dale RC;
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):127-137. PubMed ID: 29142145
[TBL] [Abstract][Full Text] [Related]
11. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes.
Duignan S; Wright S; Rossor T; Cazabon J; Gilmour K; Ciccarelli O; Wassmer E; Lim M; Hemingway C; Hacohen Y
Dev Med Child Neurol; 2018 Sep; 60(9):958-962. PubMed ID: 29468668
[TBL] [Abstract][Full Text] [Related]
12. Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Rempe T; Rodriguez E; Elfasi A; Alkabie S; Perero MM; Castrodad-Molina R; Cuascut FX; Hutton GJ; Kinkel R; Graves J
Mult Scler Relat Disord; 2024 Jul; 87():105672. PubMed ID: 38749350
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in MOG-antibody spectrum disorder: a case report.
Novi G; Gastaldi M; Franciotta D; Pesce G; Benedetti L; Uccelli A
Mult Scler Relat Disord; 2019 Jan; 27():312-314. PubMed ID: 30469022
[TBL] [Abstract][Full Text] [Related]
14. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.
Mariotto S; Ferrari S; Monaco S; Benedetti MD; Schanda K; Alberti D; Farinazzo A; Capra R; Mancinelli C; De Rossi N; Bombardi R; Zuliani L; Zoccarato M; Tanel R; Bonora A; Turatti M; Calabrese M; Polo A; Pavone A; Grazian L; Sechi G; Sechi E; Urso D; Delogu R; Janes F; Deotto L; Cadaldini M; Bianchi MR; Cantalupo G; Reindl M; Gajofatto A
J Neurol; 2017 Dec; 264(12):2420-2430. PubMed ID: 29063242
[TBL] [Abstract][Full Text] [Related]
15. Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome.
Wong YYM; Hacohen Y; Armangue T; Wassmer E; Verhelst H; Hemingway C; van Pelt ED; Catsman-Berrevoets CE; Hintzen RQ; Deiva K; Lim MJ; Rostásy K; Neuteboom RF
Eur J Neurol; 2018 May; 25(5):782-786. PubMed ID: 29443442
[TBL] [Abstract][Full Text] [Related]
16. [Isolated area postrema syndrome with anti-MOG antibodies, a rare association].
Paviolo JP; Tkachuk VA
Rev Neurol; 2020 Aug; 71(3):125-126. PubMed ID: 32672352
[TBL] [Abstract][Full Text] [Related]
17. Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases.
Rigal J; Ciron J; Lépine Z; Biotti D
Mult Scler Relat Disord; 2020 Jun; 41():102019. PubMed ID: 32151983
[TBL] [Abstract][Full Text] [Related]
18. 'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease.
Hacohen Y; Rossor T; Mankad K; Chong W'; Lux A; Wassmer E; Lim M; Barkhof F; Ciccarelli O; Hemingway C
Dev Med Child Neurol; 2018 Apr; 60(4):417-423. PubMed ID: 29288492
[TBL] [Abstract][Full Text] [Related]
19. E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
Bruijstens AL; Wendel EM; Lechner C; Bartels F; Finke C; Breu M; Flet-Berliac L; de Chalus A; Adamsbaum C; Capobianco M; Laetitia G; Hacohen Y; Hemingway C; Wassmer E; Lim M; Baumann M; Wickström R; Armangue T; Rostasy K; Deiva K; Neuteboom RF
Eur J Paediatr Neurol; 2020 Nov; 29():41-53. PubMed ID: 33176999
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases.
Hyun JW; Woodhall MR; Kim SH; Jeong IH; Kong B; Kim G; Kim Y; Park MS; Irani SR; Waters P; Kim HJ
J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):811-817. PubMed ID: 28684532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
